Dr Roopinder Gillmore, Consultant Medical Oncologist, and Peter Landstrom, Chief Executive, highlight the significant improvement in cancer treatment performance with a goal of achieving 85% from a previous 50% in its 62-day cancer performance measure. Key factors include the expansion of the cancer leadership team, robust protected learning time management, innovative pathways like nurse-led diagnostics, and close collaboration between the cancer team and health units.

Prioritising cancer as a strategic focus has created a buzz and ambition within the teams. Despite being previously among the lowest performers, the trust has been unapologetically ambitious, focusing on both basic patient care and advanced pathway improvements driven by clinical and operational teams, emphasising the importance of cancer care and patient outcomes.